Evidence map›Paper›PMID 35955620›Full record

ArticleInternational journal of molecular sciences2022

Maximising the Use of Scarce qPCR Master Mixes.

Stephen Bustin, Claire Bustin, Sara Kirvell, Tania Nolan, Reinhold Mueller, Gregory Shipley

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stephen BustinMedical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, UK.ORCID 0000-0003-1870-6098
Claire BustinRoyal Wolverhampton NHS Trust, Wolverhampton WV10 0QP, UK.
Sara KirvellMedical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, UK.
Tania NolanMedical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, UK.
Reinhold MuellerRM Consulting, San Diego, CA 92037, USA.
Gregory ShipleyShipley Consulting, Vancouver, WA 98682, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic resulted in a universal, immediate, and vast demand for comprehensive molecular diagnostic testing, especially real-time quantitative (qPCR)-based methods. This rapidly triggered a global shortage of testing capacity, equipment, and reagents. Even today, supply times for chemicals from date of order to delivery are often much longer than pre-pandemic. Furthermore, many companies have ratcheted up the price for minimum volumes of reaction master mixes essential for qPCR assays, causing additional problems for academic laboratories often operating on a shoestring. We have validated two strategies that stretch reagent supplies and, whilst particularly applicable in case of scarcity, can readily be incorporated into standard qPCR protocols, with appropriate validation. The first strategy demonstrates equivalent performance of a selection of "past expiry date" and newly purchased master mixes. This approach is valid for both standard and fast qPCR protocols. The second validates the use of these master mixes at less than 1x final concentration without loss of qPCR efficiency or sensitivity.

Indexed as

COVID-19PandemicsHumansReal-Time Polymerase Chain ReactionSensitivity and Specificitymolecular diagnosticsPCRPCR efficiencyqPCRsensitivity

Identifiers

PMID35955620
PMCPMC9368830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.